Based on the Ginkgo Bioworks Holdings stock forecast from 5 analysts, the average analyst target price for Ginkgo Bioworks Holdings is USD 2.15 over the next 12 months. Ginkgo Bioworks Holdings’s average analyst rating is Hold . Stock Target Advisor’s own stock analysis of Ginkgo Bioworks Holdings is Slightly Bearish, which is based on 3 positive signals and 6 negative signals. At the last closing, Ginkgo Bioworks Holdings’s stock price was USD 0.8705000000000001. Ginkgo Bioworks Holdings’s stock price has changed by -4.71% over the past week, -18.64% over the past month and -33.55% over the last year.
No recent analyst target price found for Ginkgo Bioworks Holdings
No recent average analyst rating found for Ginkgo Bioworks Holdings
Company Overview Ginkgo Bioworks Holdings
Ginkgo Bioworks Holdings, Inc., together with its subsidiaries, develops platform for cell programming in the United States. Its platform is used to program cells to enable biological production of products, such as novel therapeutics, food ingredients, and chemicals derived from petroleum. It serves pharma and biotech, agriculture, industrial and environment, food and nutrition, consumer and technology, and government and defense industries. Ginkgo Bioworks Holdings, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts. Read Less
Ginkgo Bioworks Holdings, Inc., together with its subsidiaries, develops platform for cell programming in the United States. Its platform is used to program cells to enable biological production of products, such as novel therapeutics, food ingredients, and chemicals derived from...Read More
Frequently Asked Questions About Ginkgo Bioworks Holdings (DNA) Stock
Based on ratings from 5 analysts Ginkgo Bioworks Holdings's stock is Hold . Stock Target Advisor's fundamental analysis is Slightly Bearish. The stock has 1 buy, 1 sell and 3 hold ratings.
Unfortunately we do not have enough data on DNA's stock to indicate if its a good dividend stock.
Based on targets from 5 analysts, the average taret price for DNA is USD 2.15 over the next 12 months. The maximum analyst target price is USD 3 while the minimum anlayst target price is USD 1.1.
DNA stock's Price/Earning ratio is 12.00.
Our analysis grades DNA stock's Price / Earning ratio at F. This means that DNA stock's Price/Earning ratio is above 50% of the stocks in the Biotechnology sector in the NYE exchange.
Based on this DNA may be fairly valued for its sector
The last closing price of DNA's stock was USD 0.87.
The most recent market capitalization for DNA is USD 2.17B.
Based on targets from 5 analysts, the average taret price for DNA is projected at USD 2.15 over the next 12 months.
This means that DNA's stock price may go up by +146.98% over the next 12 months.
We can't find any ETFs which contains Ginkgo Bioworks Holdings's stock.
As per our most recent records Ginkgo Bioworks Holdings has 1,218 Employees.
Ginkgo Bioworks Holdings's registered address is 27 Drydock Avenue, Boston, MA, United States, 02210.
You can get more information about it from Ginkgo Bioworks Holdings's website at https://www.ginkgobioworks.com.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
Low volatility
The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.
Superior return on assets
The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.
High market capitalization
This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.
What not to like
Overpriced compared to earnings
The stock is trading high compared to its peers on a price to earning basis and is above the sector median.
Below median dividend returns
The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.
Poor risk adjusted returns
This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.
Negative cashflow
The company had negative total cash flow in the most recent four quarters.
Negative free cash flow
The company had negative total free cash flow in the most recent four quarters.
Low Earnings Growth
This stock has shown below median earnings growth in the previous 5 years compared to its sector
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for DNA !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
Stocktwits
